

# GROWTH OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS IN CHINA

*An In-depth Study of Emerging Opportunities*

ISBN 978-1-934106-39-6



**NEW!** Comprehensive In-depth Study provides detailed analysis of the CMO industry, its recent development and trends. Profiles of China's Contract Manufacturing Organizations (CMOs) and Contract Development Manufacturing Organizations (CDMOs), including their capacity, history, products, scale, management, business focus, products, R&D, business and partnering strategies, strengths and weaknesses, and future objectives.

## TABLE OF CONTENTS

**Chapter 1:** Introduction: Brief History of China Biopharma Service Industry

**Chapter 2:** Legal Framework of MAH, Government Subsidy Program and Implications

**Chapter 3:** Innovation in China Biopharma and the Outsourcing of Commercial Scale Bioprocessing

**Chapter 4:** Using China-based Biologics CMOs

**Chapter 5:** China-based Biologics CMOs

**Chapter 6:** Domestic Biologics CDMOs vs. MNC Biologics CDMOs

**Appendix:** Featuring Biopharmaceutical-devoted CDMOs, Companies with Biologics Development and CMO Operations, and De-veloper companies, Also CMOs

**Coverage of Top CMO/CDMO Industry Leaders include:**

3S Guojian

Asymchem

AutekBio

Boehringer-Ingel-

heim Shanghai

Canton Bio

CC Pharming

Celgen Pharma

Celltrion

Chempartner

C-Mab

Genescript

HJB (Transcenta

Holding)

Jiangsu T-Mab

JOINN Biologics

Lonza

Mabplex, and more

[CLICK HERE FOR MORE INFORMATION and TABLE OF CONTENTS](#)

## HIGHLIGHTS

- Top Ranked CMO/CDMO Facilities in China
- Trends in the importance of Contract Manufacturing of biologics in China
- How CMOs are meeting the increased demand and rapid capacity expansions
- Analysis and Profile Directory of CMOs in China

**Much more...**

## TOPLINE FINDINGS

- China mAb Therapeutics expected to grow to USD \$26 billion by 2030, with CMOs accessing an increasing share of domestic production.
- Pipeline Growth in China is accelerating, as are markets for mAb therapeutics and vaccines
- Demand for biologics from domestic developers is increasing at 20% annually

## BY THE NUMBERS:

- Over 75+ Chinese-owned Contract Manufacturing Organizations, plus up-and-coming facilities!
- 140+ pages
- Over 30+ Figures and 20 Tables

## WHY THIS REPORT:

This study will assist Western CMOs, and biopharma developers to make strategic decisions on why and when they should enter China market.

- **Identify** potential clients and partners in China for Western CMOs
- **Analysis** for Western mAb developers in partnering with China-based biologics CMO

**Top Ranked China CMO Facilities  
ORDER YOUR COPY TODAY!**

**Order Global  
e-License \$3450**

**Order Print  
\$2450**

Publisher: BioPlan Associates, Inc.  
June 2020  
ISBN: 978-1-934106-39-6